Trametinib and Everolimus for the Treatment of Pediatric and Young Adult Patients With Recurrent Low Grade Gliomas (PNOC021)

Condition:   Recurrent World Health Organization (WHO) Grade II Glioma Interventions:   Drug: Everolimus;   Drug: Trametinib Sponsors:   University of California, San Francisco;   Novartis Pharmaceuticals;   Pediatric Brain Tumor Foundation;   The Lilabean Foundation for Pediatric Brain Cancer Research Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials